These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20235353)

  • 1. [Role of renal anemia in progression of chronic kidney disease].
    Racki S; Maleta I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S; Schiller B
    Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Erythropoesis-stimulating agents: past, present and future].
    Kes P; Basić-Jukić N
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia in renal disease: diagnosis and management.
    Lankhorst CE; Wish JB
    Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
    Agarwal AK; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoiesis-stimulating agents and heart failure.
    Lipšic E; van der Meer P; van Veldhuisen DJ
    Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for treatment of anemia of chronic kidney disease.
    Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J; Gassmann-Mayer C; Frei D; McClellan W
    Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
    Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
    Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
    Singh AK; Hertello P
    Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.